共 50 条
Survival outcomes following salvage abdominoperineal resection for recurrent and persistent anal squamous cell carcinoma
被引:1
作者:
Kitaguchi, Daichi
[1
]
Tsukada, Yuichiro
[1
]
Ito, Masaaki
[1
]
Horasawa, Satoshi
[2
]
Bando, Hideaki
[2
]
Yoshino, Takayuki
[2
]
Yamada, Kazutaka
[3
]
Ajioka, Yoichi
[4
]
Sugihara, Kenichi
[5
]
机构:
[1] Natl Canc Ctr Hosp East, Dept Colorectal Surg, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, 6-5-1 Kashiwanoha, Kashiwa, Chiba 2778577, Japan
[3] Coloproctol Ctr Takano Hosp, Dept Surg, 3-2-55,Oe,Chuo Ku, Kumamoto 8620971, Japan
[4] Niigata Univ, Div Mol & Diagnost Pathol, Grad Sch Med & Dent Sci, 8050 Ikarashi 2 Cho,Nishi Ku, Niigata 9502181, Japan
[5] Tokyo Med & Dent Univ, 1-5-45 Yushima,Bunkyo Ku, Tokyo 1138510, Japan
来源:
EJSO
|
2023年
/
49卷
/
09期
关键词:
Anal canal cancer;
Squamous cell carcinoma;
Salvage abdominoperineal resection;
Locoregional failure;
Recurrent disease;
Persistent disease;
EPIDERMOID CARCINOMA;
RANDOMIZED-TRIAL;
SURGICAL SALVAGE;
CANCER;
CHEMORADIATION;
RADIOTHERAPY;
ANUS;
CHEMOTHERAPY;
THERAPY;
MITOMYCIN;
D O I:
10.1016/j.ejso.2023.05.004
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Introduction: The primary treatment for locoregional failure following chemoradiotherapy for squamous cell carcinoma of the anus (SCCA) is salvage abdominoperineal resection (APR). However, it is necessary to distinguish between recurrent and persistent diseases because of their varied pathologies. We aimed to clarify the survival outcomes following salvage APR for recurrent and persistent diseases and investigate the significance of salvage APR. Materials and methods: This multicentre retrospective cohort study used clinical data from 47 hospitals. All patients were diagnosed with SCCA and underwent definitive radiotherapy as the primary treatment between 1991 and 2015. Overall survival (OS) was compared between the following cohorts: salvage APR for recurrence, salvage APR for persistence, non-salvage APR for recurrence, and non-salvage APR for persistence.Results: Five-year OS of salvage APR for recurrence, salvage APR for persistence, non-salvage APR for recurrence, and non-salvage APR for persistence were 75% (46%-90%), 36% (21%-51%), 42% (21%-61%), and 47% (33%-60%), respectively. OS of salvage APR for the recurrent disease was significantly higher than that for persistent disease (p = 0.00597). For recurrent disease, OS following salvage APR was significantly higher than that following non-salvage APR (p = 0.0204); however, for persistent disease, there was no significant difference between salvage and non-salvage APR (p = 0.928).Conclusion: Survival outcomes following salvage APR for persistent disease were significantly worse than that for recurrent disease. Salvage APR did not improve survival outcomes for persistent disease compared to non-salvage APR. These results will elicit a review of persistent disease treatment strategies.(c) 2023 Elsevier Ltd, BASO -The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页数:8
相关论文